ArticleHeliyon2023
Evaluation of a temperature-responsive magnetotocosome as a magnetic targeting drug delivery system for sorafenib tosylate anticancer drug.
Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- 4D printing polymeric biomaterials for adaptive tissue regeneration.Bioactive materials · 2025Review
- Impacts of designed vanillic acid-polymer-magnetic iron oxide nanocomposite on breast cancer cells.Heliyon · 2024Article
- Novel Drug Delivery Systems: An Important Direction for Drug Innovation Research and Development.Pharmaceutics · 2024Review
- Efficient drug delivery potential and antimicrobial activity of biocompatible hydrogels of dextrin/Na-alginate/PVA.Heliyon · 2024Article
- Lipid-Based Nanotechnology: Liposome.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this investigation, a polymeric fusion of chitosan (CS) and thermosensitive poly (N-isopropyl acrylamide) - PNIPAAm - encapsulated a magnetotocosome, biocompatible nanocarrier. This encapsulation strategy demonstrated improved drug entrapment efficiency, achieving up to 98.8 %. Additionally, it exhibited extended stability, optimal particle dimensions, and the potential for industrial scaling, thus facilitating controlled drug delivery of sorafenib tosylate to cancerous tissue. Reversible Addition-Fragmentation Chain Transfer (RAFT) techniques were employed to synthesize PNIPAAm. The effects of polymer molecular weight and polydispersity index on the lower critical solution temperature (LCST) were evaluated. The resulting polymeric amalgamation, involving the thermosensitive PNIPAAm synthesized using RAFT techniques and CS that coated the magnetotocosome (CS-Raft PNIPAAm-magnetotocosome) with an LCST approximately at 45 °C, holds the potential to enhance drug bioavailability and enable applications in hyperthermia treatment, controlled release, and targeted drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.